This table lists all the major pharma collaborations, acquisitions and mergers agreed during March 2014.
For an indepth analysis of these deals, read ‘Pharma deals during March 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Vidara Therapeutics/ Horizon Pharma |
Merger/ acquisition | Actimmune (interferon gamma-1b) for CGD and SMO (approved) | 660 |
| Five Prime Therapeutics/ BMS | Collaboration, licence | Drug discovery against two undisclosed targets in immune checkpoint pathways | 350.5 |
| AnaptysBio/ Tesaro | Collaboration, licence | mAbs to activate immune system response “checkpoints” – 3 targets: TIM-3, LAG-3 and PD-1 (preclinical) | 341 |
| Revive Pharmaceuticals/ Concordia Healthcare | Product acquisition | Donnatal, adjunctive therapy for IBS and acute enterocolitis (marketed) | 265.3 |
| *Takeda Pharmaceutical/ Otsuka Pharmaceutical | Co-promotion | TAK-438 (vonoprazan fumarate) for acid-related diseases (NDA filed JP) | 195+ |
| Galapagos/ Charles River | Acquisition of CRO business | Drug discovery services business | 185 |
| Activaero/ Vectura | Acquisition (cash + equity) | Portfolio of nebuliser-based respiratory products and technologies | 181 |
| Caisson Biotech/ Novo Nordisk | Licence | HEPtune drug delivery technology for half-life extension – insulin and other therapeutics (preclinical) | 167 |
| UCB/ Sanofi | Collaboration – discovery/ development | Anti-inflammatory small molecules for treatment of immune-mediated disorders (discovery) | 138.5 |
| TxCell/ Ferring | Collaboration, option, licence | Ovasave – personalised cell-based immunotherapy for IBD (inc Crohn’s disease, ulcerative colitis) (p2) | 105 |
| Sumitomo Chemical/ AstraZeneca | Acquisition of remaining shares | AZ takes complete control of AstraZeneca KK | 102 |
| **Bayer/ Kythera Biopharmaceuticals | Buy back of rights ex US, Canada (Aug 2010 deal) | ATX-101 – submental contouring injectable drug (p3) | 84 |
| Sarasvati Venture Capital/ GSK | Acquisition of remaining 30% shares | GSK takes full control of its Indonesian consumer health unit | 26.6 |
| ‡SK Chemicals/ Sanofi Pasteur | Collaboration | Pneumococcal conjugate vaccine (PCV) | 23 |
| Genmab/ Janssen | Milestone payment | Daratumumab, anti-CD38 mAb for multiple myeloma (p2 milestone) | 22 |
| Tracon Pharmaceuticals/ Santen Pharmaceutical Co | Licence | Tracon’s anti‐endoglin antibodies, including TRC105 for wet AMD (p2) | 10 |
| ‡‡BioAlliance Pharma/ Innocutis | Licence | Sitavig® (acyclovir Lauriad®) for recurrent herpes labialis (approved) | 5 |
All deals are worldwide unless otherwise noted – see below:
* Japan
** Outside US, Canada
‡ Sanofi Pasteur has rights outside Korea; SK has exclusive rights for Korea
‡‡ North America
CGD = chronic granulomatous disease
SMO = severe, malignant osteopetrosis